Natixis Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$270M Sell
550,207
-38,598
-7% -$20.9M 0.38% 57
2025
Q4
$341M Buy
588,805
+106,375
+22% +$60.2M 0.48% 27
2025
Q3
$234M Buy
482,430
+75,993
+19% +$35.4M 0.34% 51
2025
Q2
$165M Sell
406,437
-90,883
-18% -$38M 0.26% 76
2025
Q1
$247M Buy
497,320
+68,455
+16% +$37.1M 0.46% 38
2024
Q4
$223M Sell
428,865
-73,218
-15% -$40.3M 0.42% 44
2024
Q3
$311M Buy
502,083
+84,710
+20% +$50.1M 0.61% 24
2024
Q2
$231M Buy
417,373
+40,942
+11% +$23.5M 0.5% 32
2024
Q1
$219M Buy
376,431
+43,333
+13% +$24.3M 0.5% 34
2023
Q4
$177M Buy
333,098
+4,214
+1% +$2.04M 0.47% 43
2023
Q3
$166M Buy
328,884
+59,716
+22% +$31.8M 0.51% 36
2023
Q2
$140M Sell
269,168
-9,276
-3% -$5.01M 0.43% 43
2023
Q1
$160M Buy
278,444
+27,213
+11% +$15.3M 0.55% 28
2022
Q4
$138M Buy
251,231
+30,706
+14% +$16.3M 0.52% 29
2022
Q3
$112M Buy
220,525
+25,639
+13% +$14.3M 0.47% 38
2022
Q2
$106M Buy
194,886
+7,144
+4% +$3.93M 0.47% 42
2022
Q1
$111M Sell
187,742
-66,239
-26% -$38.1M 0.42% 45
2021
Q4
$169M Buy
253,981
+3,431
+1% +$2.14M 0.65% 21
2021
Q3
$143M Buy
250,550
+6,056
+2% +$3.32M 0.59% 27
2021
Q2
$123M Buy
244,494
+36,479
+18% +$17.2M 0.58% 30
2021
Q1
$94.9M Sell
208,015
-30,607
-13% -$14.6M 0.5% 38
2020
Q4
$111M Buy
238,622
+9,200
+4% +$4.31M 0.64% 24
2020
Q3
$101M Sell
229,422
-31,691
-12% -$13.1M 0.64% 25
2020
Q2
$94.6M Buy
261,113
+29,478
+13% +$9.88M 0.63% 27
2020
Q1
$65.7M Buy
231,635
+17,927
+8% +$5.65M 0.54% 36
2019
Q4
$69.4M Sell
213,708
-6,467
-3% -$1.96M 0.49% 43
2019
Q3
$64.1M Buy
220,175
+6,101
+3% +$1.75M 0.51% 40
2019
Q2
$62.9M Buy
214,074
+8,427
+4% +$2.32M 0.51% 44
2019
Q1
$56.3M Buy
205,647
+7,094
+4% +$1.77M 0.49% 43
2018
Q4
$44.4M Buy
198,553
+1,048
+0.5% +$246K 0.44% 45
2018
Q3
$48.2M Buy
197,505
+10,443
+6% +$2.4M 0.42% 46
2018
Q2
$38.7M Buy
187,062
+17,475
+10% +$3.71M 0.37% 52
2018
Q1
$35M Buy
169,587
+10,460
+7% +$2.2M 0.35% 55
2017
Q4
$30.2M Buy
159,127
+5,752
+4% +$1.1M 0.31% 62
2017
Q3
$29M Sell
153,375
-7,790
-5% -$1.41M 0.31% 59
2017
Q2
$28.1M Sell
161,165
-7,956
-5% -$1.34M 0.3% 59
2017
Q1
$26M Buy
169,121
+16,322
+11% +$2.49M 0.29% 63
2016
Q4
$21.6M Buy
152,799
+10,771
+8% +$1.59M 0.26% 82
2016
Q3
$22.6M Sell
142,028
-13,666
-9% -$2.11M 0.29% 68
2016
Q2
$23M Sell
155,694
-2,603
-2% -$384K 0.32% 67
2016
Q1
$22.4M Buy
158,297
+21,998
+16% +$2.95M 0.34% 59
2015
Q4
$19.3M Buy
136,299
+38,414
+39% +$5.12M 0.32% 67
2015
Q3
$12M Buy
97,885
+12,446
+15% +$1.62M 0.21% 106
2015
Q2
$11.1M Buy
85,439
+13,412
+19% +$1.75M 0.19% 128
2015
Q1
$9.68M Buy
72,027
+13,710
+24% +$1.77M 0.17% 147
2014
Q4
$7.31M Buy
58,317
+2,073
+4% +$252K 0.14% 203
2014
Q3
$6.84M Buy
56,244
+2,367
+4% +$288K 0.14% 203
2014
Q2
$6.36M Buy
53,877
+1,992
+4% +$234K 0.09% 360
2014
Q1
$6.24M Sell
51,885
-9,623
-16% -$1.14M 0.1% 349
2013
Q4
$6.85M Buy
61,508
+2,065
+3% +$205K 0.11% 300
2013
Q3
$5.48M Buy
59,443
+13,505
+29% +$1.22M 0.1% 345
2013
Q2
$3.89M Buy
+45,938
New +$3.82M 0.08% 413

Other funds holding TMO

Natixis Advisors's TMO Position: Q1 2026 in Review

Natixis Advisors reduced its Thermo Fisher Scientific (TMO) stake by 6.6% in Q1 2026, selling an estimated $20.9M and leaving 550,207 shares worth $270M. The position accounts for 0.38% of the portfolio, ranked #57.

Natixis Advisors first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $341M in Q4 2025. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Natixis Advisors held 550,207 shares of Thermo Fisher Scientific worth $270M as of Q1 2026.
  • Natixis Advisors sold 38,598 Thermo Fisher Scientific shares in Q1 2026, an estimated $20.9M.
  • Thermo Fisher Scientific made up 0.38% of Natixis Advisors's portfolio in Q1 2026, its #57 holding.
  • Natixis Advisors first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Natixis Advisors's Thermo Fisher Scientific position peaked at $341M in Q4 2025.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Natixis Advisors's 13F filing for Q1 2026, filed 13 May 2026.